337: Eli Lilly CEO on Trump, obesity drugs, and a guidance miss
The Readout Loud
Biotech M&A Dynamics at JPMorgan Conference
This chapter explores significant M&A activities in the biotech sector, focusing on Johnson & Johnson's $14.6 billion acquisition of Intracellular Therapies. It discusses market uncertainties and the mixed sentiments among industry leaders, highlighting the need for consolidation and the evolving role of AI in drug development.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
